Archive: Company News
Company News: Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge
— Initial patient samples collected for second U.S. Unyvero Product Study
— Prospective clinical trial expected to start in 2018
Curetis N.V. (the “Company” together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced it has started collecting patient samples for a multi center FDA study for its Unyvero IJI Cartridge for the detection of invasive joint infections.
Company News: Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced its participation in several industry conferences in the fourth quarter of 2017. The respective presentations will be made available on the company’s website.
Company News: New textbook describes the latest research results for the treatment of periprosthetic joint infections
— The collected volume provides a clear overview of information about the diagnosis, therapy, prevention and costs of joint infections
— Available as of October 2017
The recently published textbook ‘Management of Periprosthetic Joint Infections’ presents a clear overview of the latest developments and findings in the treatment of periprosthetic infections in hip and knee joints. The authors of the volume are renowned international experts in their particular areas, and in their contributions to the book share their many years of clinical experience using numerous clinical case studies. The editor is Professor Klaus-Dieter Kühn of the Medical University of Graz and Senior Scientific Advisor at Heraeus Medical.
Company News: BioNTech Manufacturing Subsidiary, EUFETS, Becomes BioNTech Innovative Manufacturing Services
– Expansion and re-branding to ensure continued growth –
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that its manufacturing subsidiary, EUFETS GmbH, has been re-branded as BioNTech Innovative Manufacturing Services. Furthermore, to prepare for further growth in response to increasing demand for cell and gene therapy products, in particular for CAR-T and T-Cell immunotherapies, BioNTech Innovative Manufacturing Services will significantly increase its production capacity by doubling cleanroom space and expanding development and quality control areas in a new facility.